Cargando…

Reduction of MHC-I expression limits T-lymphocyte-mediated killing of Cancer-initiating cells

BACKGROUND: It has been proposed that cancer establishment, maintenance, and recurrence may be attributed to a unique population of tumor cells termed cancer-initiating cells (CICs) that may include characteristics of putative cancer stem cell-like cells. Studies in lung cancer have shown that such...

Descripción completa

Detalles Bibliográficos
Autores principales: Morrison, Brian J., Steel, Jason C., Morris, John C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5918869/
https://www.ncbi.nlm.nih.gov/pubmed/29699516
http://dx.doi.org/10.1186/s12885-018-4389-3
_version_ 1783317509704777728
author Morrison, Brian J.
Steel, Jason C.
Morris, John C.
author_facet Morrison, Brian J.
Steel, Jason C.
Morris, John C.
author_sort Morrison, Brian J.
collection PubMed
description BACKGROUND: It has been proposed that cancer establishment, maintenance, and recurrence may be attributed to a unique population of tumor cells termed cancer-initiating cells (CICs) that may include characteristics of putative cancer stem cell-like cells. Studies in lung cancer have shown that such cells can be enriched and propagated in vitro by culturing tumor cells in serum-free suspension as tumorspheres. CICs have been characterized for their phenotype, stem cell-like qualities, and their role in establishing tumor and maintaining tumor growth. Less is known about the interaction of CICs with the immune system. METHODS: We established CIC-enriched tumorspheres from murine TC-1 lung cancer cells, expressing human papillomavirus 16 (HPV-16) E6/E7 antigens, and evaluated their susceptibility to antitumor immune responses both in vitro and in vivo. RESULTS: TC-1 CICs demonstrated reduced expression of surface major histocompatibility complex (MHC)-I molecules compared to non-CICs. We similarly determined decreased MHC-I expression in five of six human lung cancer cell lines cultured under conditions enriching for CICs. In vivo, TC-1 cells enriched for CICs were resistant to human papillomavirus 16 E6/E7 peptide vaccine-mediated killing. We found that vaccinated mice challenged with CIC enriched tumorspheres demonstrated shorter survivals and showed significantly fewer CD8(+) tumor infiltrating lymphocytes compared to CIC non-enriched challenged mice. Furthermore, cultured cytotoxic T lymphocytes (CTLs) from vaccinated mice demonstrated reduced capacity to lyse TC-1 cells enriched for CICs compared to non-enriched TC-1 cells. Following treatment with IFN-γ, both CIC enriched and non-enriched TC-1 cells expressed similar levels of MHC-I, and the increased MHC-I expression on CICs resulted in greater CTL-mediated tumor lysis and improved tumor-free survival in mice. CONCLUSIONS: These results suggest that the attenuated expression of MHC-I molecules by CICs represents a potential strategy of CICs to escape immune recognition, and that the development of successful immunotherapy strategies targeting CICs may decrease their resistance to T cell-mediated immune detection by enhancing CIC MHC-I expression. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12885-018-4389-3) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5918869
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-59188692018-04-30 Reduction of MHC-I expression limits T-lymphocyte-mediated killing of Cancer-initiating cells Morrison, Brian J. Steel, Jason C. Morris, John C. BMC Cancer Research Article BACKGROUND: It has been proposed that cancer establishment, maintenance, and recurrence may be attributed to a unique population of tumor cells termed cancer-initiating cells (CICs) that may include characteristics of putative cancer stem cell-like cells. Studies in lung cancer have shown that such cells can be enriched and propagated in vitro by culturing tumor cells in serum-free suspension as tumorspheres. CICs have been characterized for their phenotype, stem cell-like qualities, and their role in establishing tumor and maintaining tumor growth. Less is known about the interaction of CICs with the immune system. METHODS: We established CIC-enriched tumorspheres from murine TC-1 lung cancer cells, expressing human papillomavirus 16 (HPV-16) E6/E7 antigens, and evaluated their susceptibility to antitumor immune responses both in vitro and in vivo. RESULTS: TC-1 CICs demonstrated reduced expression of surface major histocompatibility complex (MHC)-I molecules compared to non-CICs. We similarly determined decreased MHC-I expression in five of six human lung cancer cell lines cultured under conditions enriching for CICs. In vivo, TC-1 cells enriched for CICs were resistant to human papillomavirus 16 E6/E7 peptide vaccine-mediated killing. We found that vaccinated mice challenged with CIC enriched tumorspheres demonstrated shorter survivals and showed significantly fewer CD8(+) tumor infiltrating lymphocytes compared to CIC non-enriched challenged mice. Furthermore, cultured cytotoxic T lymphocytes (CTLs) from vaccinated mice demonstrated reduced capacity to lyse TC-1 cells enriched for CICs compared to non-enriched TC-1 cells. Following treatment with IFN-γ, both CIC enriched and non-enriched TC-1 cells expressed similar levels of MHC-I, and the increased MHC-I expression on CICs resulted in greater CTL-mediated tumor lysis and improved tumor-free survival in mice. CONCLUSIONS: These results suggest that the attenuated expression of MHC-I molecules by CICs represents a potential strategy of CICs to escape immune recognition, and that the development of successful immunotherapy strategies targeting CICs may decrease their resistance to T cell-mediated immune detection by enhancing CIC MHC-I expression. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12885-018-4389-3) contains supplementary material, which is available to authorized users. BioMed Central 2018-04-26 /pmc/articles/PMC5918869/ /pubmed/29699516 http://dx.doi.org/10.1186/s12885-018-4389-3 Text en © The Author(s). 2018 https://creativecommons.org/publicdomain/zero/1.0/COPYRIGHT NOTICE. The article is a work of the United States Government; Title 17 U.S.C 105 provides that copyright protection is not available for any work of the United States Government in the United States. Additionally, this is an open access article distributed under the terms of the Creative Commons Public Domain Dedication waiver http://creativecommons.org/publicdomain/zero/1.0 (https://creativecommons.org/publicdomain/zero/1.0/) , which permits worldwide unrestricted use, distribution, ond reproduction in any medium for any lawful purpose.
spellingShingle Research Article
Morrison, Brian J.
Steel, Jason C.
Morris, John C.
Reduction of MHC-I expression limits T-lymphocyte-mediated killing of Cancer-initiating cells
title Reduction of MHC-I expression limits T-lymphocyte-mediated killing of Cancer-initiating cells
title_full Reduction of MHC-I expression limits T-lymphocyte-mediated killing of Cancer-initiating cells
title_fullStr Reduction of MHC-I expression limits T-lymphocyte-mediated killing of Cancer-initiating cells
title_full_unstemmed Reduction of MHC-I expression limits T-lymphocyte-mediated killing of Cancer-initiating cells
title_short Reduction of MHC-I expression limits T-lymphocyte-mediated killing of Cancer-initiating cells
title_sort reduction of mhc-i expression limits t-lymphocyte-mediated killing of cancer-initiating cells
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5918869/
https://www.ncbi.nlm.nih.gov/pubmed/29699516
http://dx.doi.org/10.1186/s12885-018-4389-3
work_keys_str_mv AT morrisonbrianj reductionofmhciexpressionlimitstlymphocytemediatedkillingofcancerinitiatingcells
AT steeljasonc reductionofmhciexpressionlimitstlymphocytemediatedkillingofcancerinitiatingcells
AT morrisjohnc reductionofmhciexpressionlimitstlymphocytemediatedkillingofcancerinitiatingcells